Point-of-Care NSE Biosensor for Objective Assessment of Stroke Risk
Biosensors · 2025
DOI: 10.3390/bios15040264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors, 2025. Verfasst von Cheng Hsu Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Critical Care Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan. Hauptthemen laut MEDLINE: Biosensing Techniques, Stroke, Phosphopyruvate Hydratase, Point-of-Care Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiwan National Science and Technology Council, Center for Intelligent Drug Systems and Smart Biodevices (IDS2B), Center for Regenerative Medicine and Cellular Therapy.
Themen: Schlaganfall
Abstract (Originalsprache)
The rapid identification of stroke is critical to improving stroke patient outcomes. Existing protocols for assessing the risk of stroke are subjective and may be further complicated by nonspecific symptoms, increasing the risk of misdiagnosis. Neuron-specific enolase (NSE) has emerged as a promising stroke biomarker. However, current detection methods such as the electrochemiluminescence immunoassay (ECLIA) are time-consuming and costly. In this research, we developed an electrochemical biosensor for the rapid quantification of NSE in whole blood. Mouse stroke models were established, and blood samples collected were analyzed using both hospital-standard ECLIA as well as the biosensor. The biosensor limit of detection was 1.15 ng/mL. NSE measurements were highly correlated between the two methods and were obtained in 5 min using 20 μL of unprocessed whole blood samples. Notably, the biosensor could accurately quantify elevated blood NSE blood that was associated with more severe stroke. Our results demonstrate the utility of the proposed biosensor in pre-hospital settings. Combined with existing stroke assessment methods, the biosensor may enable emergency personnel to identify stroke risk with greater accuracy to optimize the chances of receiving necessary treatment within the effective window.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency and Critical Care Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan.
- Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan.
- Industrial Development Graduate Program of College of Engineering and Bioscience, National Yang Ming Chiao Tung University, Hsinchu 30010, Taiwan.
- AgriTalk Technology Inc., Hsinchu 30010, Taiwan.
- Department of Post Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan.
- Department of Nursing, Chang Jung Christian University, Tainan 71101, Taiwan.
ORCID-Profile: Cheng Hsu Chen, Tsung-Han Lee, Yan-Ren Lin
Förderung
- Taiwan National Science and Technology Council
- Center for Intelligent Drug Systems and Smart Biodevices (IDS2B)
- Center for Regenerative Medicine and Cellular Therapy
Zitieren
APA
Hsu Chen, C., Wang, E., Lee, T. H., Huang, C. C., Tai, C. S., Lin, Y. R., & Chen, W. L. (2025). Point-of-Care NSE Biosensor for Objective Assessment of Stroke Risk. Biosensors. https://doi.org/10.3390/bios15040264
Vancouver
Hsu Chen C, Wang E, Lee TH, Huang CC, Tai CS, Lin YR, et al. Point-of-Care NSE Biosensor for Objective Assessment of Stroke Risk. Biosensors. 2025. doi:10.3390/bios15040264
BibTeX
@article{HsuChen2025,
author = {Hsu Chen, Cheng and Wang, Erick and Lee, Tsung-Han and Huang, Cheng-Chieh and Tai, Chun-San and Lin, Yan-Ren and Chen, Wen-Liang},
title = {Point-of-Care NSE Biosensor for Objective Assessment of Stroke Risk},
journal = {Biosensors},
year = {2025},
doi = {10.3390/bios15040264}
}
EUVIMED